<DOC>
	<DOCNO>NCT00985855</DOCNO>
	<brief_summary>Phase II , randomise , control , non comparative study 2 parallel group : - Arm A : patient receive induction chemotherapy ( cisplatin docetaxel ) follow concomitant radio-chemotherapy include 2 cycle cisplatin vinorelbine associate weekly cetuximab infusion radiotherapy . - Arm B : patient receive induction chemotherapy ( cisplatin docetaxel ) follow concomitant radio-chemothérapy include 2 cycle cisplatin etoposide associate weekly cetuximab infusion radiotherapy .</brief_summary>
	<brief_title>Feasibility Cetuximab Associated With Concomitant Radio-Chemotherapy Patients With Locally Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>NonSmallCell Lung cancer cytologically histologically proved Stage III AN2 inoperable non resectable presence least one one dimension measurable target ( least 10 mm spiral tomodensitometry ) Possibility include target one irradiation field Age 18 70 Patients non previously treat Performance Status 0 1 Loss weight ≤10 % 3 last month Neutrophil ≥ 1500/mm3 platelet ≥ 100000/mm3 Creatinine clearance ≥ 60 ml/min total bilirubin ≤ 1,5N ASAT ALAT ≤ 2,5N Respiratory function normal : VEMS ≥ 40 % theorical , DLCO/VA ≥ 50 % theorical PaO2 ≥ 60 mmHg Signed inform consent form Compliance radiotherapy 66 Gy dosimetry V20 ≤ 35 % pulmonary mean dose≤20 Gy Pretreated bronchial carcinoma , except endoscopic deobstruction operable bronchial carcinoma small cell lung cancer , composite cancer , neuroendocrine cancer , broncho alveolar cancer superior vena cava syndroms puncturable pleural effusion metastatic lung cancer Stage IIIb cancer neoplastic pericarditis Previous thoracic irradiation severe cardiac disease 12 month inclusion interstitial lung disease antiEGFR antiVEGF treatment hypersensitivity murine proteins allergy protocol drug uncontrolled infectious state HIV patient corticoid definitive contraindication péripheric neuropathy grade≥2 neurologic , psychiatric organic disorder past concomitant cancer except treated skin basocellular cancer situ cervical cancer , cancer surgically treat 5 year breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>